Addictive Potential: Unknown
Emergency Room Visits Yearly: Unknown
Mandatory Minimum Sentence: Unknown
Mechanism of Action: partial agonist of the 5HT2A receptor
25I-NBMD is also known as NBMD-2C-I, Cimbi-29, N-(2,3-methylenedioxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, and 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2,3-methylenedioxyphenyl)methyl]ethanamine. It is a psychedelic phenethylamine, acting as a potent partial agonist for the 5HT2A receptor. According to Sekula (2013), 25I-NBMD is a “derivative of the hallucinogenic substances 2C-I and 25I-NBOMe.”
Although 25I-NBMD was discovered by David Nichols’ team at Purdue University in 2006, it wasn’t available on the illicit drug market until 2012 (Sekula, 2013). Since then, it has been identified on blotter paper in Poland and discussed on numerous forum websites with users reprting dosage ranges between 500 μg and 3 mg (Sekula).
The subjective effects of “25I-NBMD include euphoria, hallucinations with eyes either open or closed, intensification of sensory stimuli (improved music perception, greater intensity of sexual experience), changes in personality and altered perception of surroundings, stimulation of creative thinking” (Sekula, 2013).
Side Effects & Adverse Reactions:
25I-NBMD is a very new substance, and little is known about its side effects, adverse reactions, long term damage, and/or addiction potential. Still Sekula (2013) noted palpitations, total disorientation, and confusion as possible negative effects.
Remember, research chemicals are experimental chemicals that are not approved for human consumption. This is because not enough data exists currently about their effects in humans. Although some people are willing to ingest research chemicals, it is unreasonable to assume that they are in any way safe to use recreationally.